Videos

Fabrice Barlesi, MD, discusses the importance of molecular testing in patients with nonsquamous non–small cell lung cancer during the World Conference on Lung Cancer in Toronto, Canada.

Jonathon B. Cohen, MD, discusses findings from a study of polatuzumab vedotin, an anti-CD79b antibody-drug conjugate, with bendamustine and rituximab in patients with aggressive lymphomas.

David Spigel, MD, medical oncologist and Chief Scientific Officer at Sarah Cannon Research Institute, discusses the updated results for the PACIFIC trial, a randomized phase III trial investigating the addition of durvalumab (Imfinzi) to chemoradiation versus placebo in patients with unresectable stage III lung cancer.

Robert C. Doebele, MD, PhD, discusses resistance in patients with ROS1-positive lung cancer.

HER2+ Early-Stage Breast Cancer: Perioperative Approaches

Andrew Zhu, MD, PhD, director of Liver Cancer Research and Medicine at Massachusetts General Hospital, shares his advice on making decisions for frontline treatment of patients with hepatocellular carcinoma.